JianYing Liang

Find an error

Name: 梁建英; JianYing Liang

Organization: Fudan University

Department: Department of Pharmaceutical Analysis, School of Pharmacy

Title: Associate Professor

Chemicals
References

Dual Functional Peptide-Driven Nanoparticles for Highly Efficient Glioma-Targeting and Drug Codelivery

Co-reporter:Yuyang Kuang; Xutao Jiang; Yu Zhang; Yifei Lu; Haojun Ma; Yubo Guo; Yujie Zhang; Sai An; Jianfeng Li; Lisha Liu; Yinhao Wu; Jianying Liang;Chen Jiang

Molecular Pharmaceutics 2016 Volume 13(Issue 5) pp:1599-1607

Publication Date(Web):April 8, 2016

DOI:10.1021/acs.molpharmaceut.6b00051

Compared with peripheral tumors, glioma is very difficult to treat, not only because it has general features of tumor but also because the therapy has been restricted by the brain–blood barrier (BBB). The two main features of tumor growth are angiogenesis and proliferation of tumor cells. RNA interference (RNAi) can downregulate VEGF overexpression to inhibit tumor neovascularization. Meanwhile, doxorubicin (DOX) has been used for cytotoxic chemotherapy to kill tumor cells. Thus, combining RNAi and chemotherapy has been regarded as a potential strategy for cancer treatment. However, the BBB limits the shVEGF-DOX codelivery system to direct into glioma. Here, a smart drug delivery system modified with a dual functional peptide was established, which could target to transferrin receptor (TfR) overexpressing on both the BBB and glioma. It showed that the dual-targeting delivery system had high tumor targeting efficiency in vitro and in vivo.

Mammary-Derived Growth Inhibitor Targeting Peptide-Modified PEG–PLA Nanoparticles for Enhanced Targeted Glioblastoma Therapy

Co-reporter:Xingye Feng, Xiaoling Gao, Ting Kang, Di Jiang, Jianhui Yao, Yixian Jing, Qingxiang Song, Xinguo Jiang, Jianying Liang, and Jun Chen

Bioconjugate Chemistry 2015 Volume 26(Issue 8) pp:1850

Publication Date(Web):July 29, 2015

DOI:10.1021/acs.bioconjchem.5b00379

Targeting delivery of chemotherapeutics to neovasculature represents a promising means for tumor therapy since angiogenesis has been a featured hallmark of glioblastma. However, anti-angiogenic therapy would induce the occurrence of metastatic tumor and even neoplasm recurrence. Simultaneous targeting of tumor cells and neovasculature perfectly overcome such defects and has been proven to be an efficacious strategy for suppressing tumor growth. In the present study, a tumor homing peptide CooP selective binding to mammary-derived growth inhibitor that overexpressed in glioma cells and blood vessel endothelial cells was decorated on the surface of paclitaxel-loading PEG–PLA nanoparticles (NP-PTX) to obtain the dual targeting nanovector CooP-NP-PTX. In vitro antiproliferation study showed that HUVEC cells and U87MG cells were much more sensitive to CooP-NP-PTX than NP-PTX. In vivo imaging demonstrated that CooP-NP accumulated more selectively and penetrated deeper into the tumor site. In addition, the glioma-bearing mice treated with CooP-NP-PTX achieved the longest survival time compared to NP-PTX and Taxol. The findings observed above indicated that CooP peptide-functionalized anti-neoplastic agent-loaded nanoparticles might possess promising potential for glioblastoma therapy.

Rapid identification of efavirenz metabolites in rats and humans by ultra high performance liquid chromatography combined with quadrupole time-of-flight tandem mass spectrometry

Co-reporter:Yachen Deng;Rong Liu;Ping Yang

Journal of Separation Science 2015 Volume 38( Issue 9) pp:1529-1536

Publication Date(Web):

DOI:10.1002/jssc.201401401

An in vivo study of efavirenz metabolites in rats and human patients with ultra high performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry combined with MetabolitePilot^MT software is reported for the first time. Considering the polarity differences between the metabolites, solid-phase extraction and protein precipitation were both applied as a part of the sample preparation method. The structures of the metabolites and their fragment ions were identified or tentatively characterized based on the accurate mass and MS² data. As a result, a total of 15 metabolites, including 11 from rat samples and 13 from human samples, were identified or tentatively characterized. Two metabolites and several new metabolism pathways are reported for the first time. This study provides a practical approach for identifying complicated metabolites through the rapid and reliable ultra high performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry technique, which could be widely used for the investigation of drug metabolites.

Screening of bioactive compounds in Rhizoma Polygoni Cuspidati with hepatocyte membranes by HPLC and LCMS

Co-reporter:Ying Xue

Journal of Separation Science 2014 Volume 37( Issue 3) pp:250-256

Publication Date(Web):

DOI:10.1002/jssc.201301020

A new method employing HPLC, LC–MS, and hepatocyte membranes for the screening of bioactive compounds in traditional Chinese medicines (TCMs) has been proposed. We hypothesized that exposure of the TCM extracts to hepatocyte membranes should decrease the concentration of membrane-permeable compounds in the solution. Using this approach, the permeability of the compounds in Rhizoma Polygoni Cuspidati was investigated. By comparing chromatograms of samples prepared both before and after interaction with hepatocyte membranes, seven permeable compounds of Rhizoma Polygoni Cuspidati were identified. Additionally, it was found that piceid, resveratrol, emodin-8-β-d-glucoside, physcion-8-β-d-glucoside, aloe-emodin, emodin, and physcion combined specifically with hepatocyte membranes, which might indicate a useful approach for revealing the antiatherosclerotic effects of Rhizoma Polygoni Cuspidati. Therefore, the proposed method could be a good approach to predict the potential bioactivities of multiple compounds in TCMs simultaneously. Based on the significance of these results, this method could be a novel approach for identifying potentially bioactive components in other TCMs.

A novel fluorescence derivatization method combined with HPLC for determining the activities of endogenous caspase

Co-reporter:Jiachi Liu, Ye Lu and Jianying Liang

Analyst 2012 vol. 137(Issue 21) pp:5097-5104

Publication Date(Web):28 Aug 2012

DOI:10.1039/C2AN35822K

A novel fluorescence derivatization method combined with HPLC was developed to detect the activity of caspase-3 and -8 in two cell lines (Hela cells and A549 cells) which were activated by low temperature-assisted ultraviolet irradiation (LT-UV), mitomycin C (MMC) and camptothecin during the apoptosis, respectively. Two peptide substrates for either caspase-3 or -8 were designed, of which peptide fragments were obtained by enzymatic modification, followed by fluorescence derivatization. A single fluorescent product was formed when a peptide was heated at 120 °C for 10 min in a neutral aqueous medium (pH 7.0) containing catechol, sodium periodate and sodium borate. Commercial kits for detecting the activity of caspase-3 and -8 were used as a control. The relative activity of the caspases detected by fluorescence derivatization was similar to that obtained by commercial kits, which indicated that the novel method is reliable. The activity assays of recombinant human caspases showed that the novel method provided higher selectivity than that of commercial kits, which proved it to be more accurate for determining the activity of caspases in apoptosis.

Screening of bioactive compounds in Radix Salviae Miltiorrhizae with liposomes and cell membranes using HPLC

Co-reporter:Xiaoping Chen, Yachen Deng, Ying Xue, Jianying Liang

Journal of Pharmaceutical and Biomedical Analysis 2012 70() pp: 194-201

Publication Date(Web):

DOI:10.1016/j.jpba.2012.06.030

Screening of permeable compounds in Flos Lonicerae Japonicae with liposome using ultrafiltration and HPLC

Co-reporter:Xiaoping Chen, Yuqin Xia, Ye Lu, Jianying Liang

Journal of Pharmaceutical and Biomedical Analysis 2011 54(2) pp: 406-410

Publication Date(Web):

DOI:10.1016/j.jpba.2010.08.028

Determination of bifendate in human plasma by HPLC–MS and bioequivalence on bifendate pills in healthy volunteers

Co-reporter:Lingjie Zhou, Lihua Gu, Yijian Wang, Jianying Liang

Journal of Pharmaceutical and Biomedical Analysis 2006 Volume 40(Issue 4) pp:1025-1030

Publication Date(Web):3 March 2006

DOI:10.1016/j.jpba.2005.08.007

A sensitive and specific method for the determination of bifendate in human plasma was developed, based on high-performance liquid chromatography (HPLC)–mass spectrometry (MS). The samples were extracted from plasma with diethyl ether, followed by separation and evaporation after addition of internal standard diazepam. The residue was reconstituted in methanol and injected into the HPLC–MS. Chromatography was performed on an Inertsil ODS column with a mobile phase consisting of methanol–distilled water (70/30, v/v) at a flow rate of 0.3 mL/min. Quantitative analysis was achieved by MS detection, using a mass spectrometer equipped with an electrospray ionization interface (ESI) and operated in selected ion monitoring (SIM) and positive-ionization mode using target ions at m/z 419 for bifendate and m/z 285 for internal standard, respectively. The linearity was confirmed in the concentration range of 2–200 ng/mL in human plasma and the precision of this assay was not more than 6.79% over the entire concentration range. The method was sensitive and repeatable enough to be used in pharmacokinetic and bioavailability studies.